Terug
75
78
Dagbereik
€ 4,35
€ 5,22
52-Weeksbereik
€ 3,43
€ 5,22
Volume
1
50D / 200D Gem.
€ 5,22
/
€ 4,66
Vorige Slotkoers
€ 5,22
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,9 | 0,4 |
| P/B | 0,4 | 2,9 |
| ROE % | 14,8 | 3,7 |
| Net Margin % | 17,5 | 3,9 |
| Rev Growth 5Y % | 2,9 | 10,0 |
| D/E | 0,3 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 2,66
€ 2,49 – € 2,76
|
13 B | 1 |
| FY2026 |
€ 2,44
€ 2,28 – € 2,54
|
12 B | 1 |
Belangrijkste Punten
Revenue grew 2,94% annually over 5 years — modest growth
ROE of 14,77% — decent returns on equity
Net margin of 17,45% shows strong profitability
Debt/Equity of 0,28 — conservative balance sheet
Generating 2,41B in free cash flow
P/E of 2,94 — trading at a low valuation
Groei
Revenue Growth (5Y)
2,94%
Revenue (1Y)-4,97%
Earnings (1Y)5,50%
FCF Growth (3Y)14,65%
Kwaliteit
Return on Equity
14,77%
ROIC11,99%
Net Margin17,45%
Op. Margin24,08%
Veiligheid
Debt / Equity
0,28
Current Ratio2,15
Interest Coverage32,10
Waardering
P/E Ratio
2,94
P/B Ratio0,44
EV/EBITDA-0,29
Dividend Yield0,06%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -4,97% | Revenue Growth (3Y) | -3,29% |
| Earnings Growth (1Y) | 5,50% | Earnings Growth (3Y) | 3,90% |
| Revenue Growth (5Y) | 2,94% | Earnings Growth (5Y) | 4,70% |
| Profitability | |||
| Revenue (TTM) | 11,81B | Net Income (TTM) | 2,06B |
| ROE | 14,77% | ROA | 8,43% |
| Gross Margin | 65,45% | Operating Margin | 24,08% |
| Net Margin | 17,45% | Free Cash Flow (TTM) | 2,41B |
| ROIC | 11,99% | FCF Growth (3Y) | 14,65% |
| Safety | |||
| Debt / Equity | 0,28 | Current Ratio | 2,15 |
| Interest Coverage | 32,10 | Dividend Yield | 0,06% |
| Valuation | |||
| P/E Ratio | 2,94 | P/B Ratio | 0,44 |
| P/S Ratio | 0,51 | PEG Ratio | 1,68 |
| EV/EBITDA | -0,29 | Dividend Yield | 0,06% |
| Market Cap | 6,06B | Enterprise Value | -830,33M |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 11,81B | 12,43B | 12,63B | 12,06B | 10,52B |
| Net Income | 2,06B | 1,95B | 1,91B | 1,78B | 1,71B |
| EPS (Diluted) | 2,24 | 2,10 | 2,04 | 1,90 | 1,83 |
| Gross Profit | 7,73B | 7,66B | 8,17B | 7,81B | 6,85B |
| Operating Income | 2,84B | 2,42B | 2,35B | 2,27B | 2,50B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 24,46B | 25,04B | 24,86B | 22,37B | 20,59B |
| Total Liabilities | 9,55B | 10,28B | 9,93B | 8,06B | 6,95B |
| Shareholders' Equity | 13,86B | 14,04B | 13,88B | 13,00B | 12,11B |
| Total Debt | 3,93B | 3,48B | 3,62B | 2,69B | 1,93B |
| Cash & Equivalents | 10,83B | 11,33B | 10,41B | 9,15B | 9,95B |
| Current Assets | 16,42B | 17,27B | 16,99B | 14,67B | 14,63B |
| Current Liabilities | 7,63B | 8,09B | 7,40B | 6,93B | 6,08B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#26 of 820
#9 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026